DoNews4月18日消息，据鳌头财经报道，近日，国货美妆头部品牌可复美深陷“EGF添加门”舆论漩涡，作为“重组胶原蛋白第一股”巨子生物（02367.HK）的核心品牌，可复美以“类人胶原蛋白”技术为卖点，主打修复与安全功效，2024年销售收入达45.42亿元，同比增长62.9%，占公司总营收的82%，堪称巨子生物的“命脉”。然而，此次事件如同一颗深水炸弹，直击品牌“安全、专业”的核心价值，股价应声...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.